APO-HYDROXYUREA (hydroxyurea) is indicated for concomitant use with irradiation therapy in the treatment of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip. Tumor responses to hydroxyurea have been reported in resistant chronic myelocytic leukemia
